Navigation Links
Thermage Reports Third Quarter Financial Results and Provides Information Regarding Reliant's Results
Date:11/10/2008

2008 2007 2008 2007

Income (loss) from

operations $(829) $(239) $(2,087) $91

Non-GAAP adjustments to

income (loss) from

operations:

Merger related costs 165 - 1,134 -

Stock-based compensation 887 1,222 2,789 3,705

Non-GAAP income from

operations $223 $983 $1,836 $3,796

GAAP net income (loss) $(1,146) $423 $(1,344) $1,790

Non-GAAP adjustments to

net income (loss):

Merger related costs, net

of taxes 131 - 1,075 -

Loss on investments, net

of taxes 863 - 863 -

Stock-based compensation,

net of taxes 887 1,222 2,789 3,705

Non-GAAP net income $735 $1,645 $3,383 $5,495

GAAP basic net income

(loss) per share $(0.05) $0.02 $(0.06) $0.08

Non-GAAP adjustments to

basic income (loss) per

share:

Merger related costs 0.01 - 0.05 -

Loss on investments 0.03 - 0.03 -

Stock-based compensation 0.04 0.05 0.12 0.16

Non-GAAP basic net income

per share $0.03 $0.07 $0.14 $0.24

Non-GAAP diluted net

income per share $0.03 $0.07 $0.14 $0.23

GAAP weighted average

shares outstanding used

in calculating basic net

income (loss) per share 24,067,548 23,364,409 23,861,079 23,151,949

Adjustments for dilutive

potential common stock 838,410 549,052 1,057,632 585,145

Weighted average
'/>"/>

SOURCE Thermage, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related medicine news :

1. Thermage Discloses Preliminary 3Q 2008 Results for Thermage and Reliant
2. Thermage, Inc. to Present at the Maxim Group Growth Conference
3. Thermage Announces Second Quarter 2008 Financial Results
4. Thermage, Inc. to Present at the Fourth Annual Collins Stewart Growth Conference
5. Thermage and Reliant Technologies to Join Forces
6. Thermage, Inc. to Present at the Bank of America 2008 Healthcare Conference
7. Thermage, a Leading Aesthetic Medical Device Company, Announces First Time Exhibitor Status at ACOG Meeting
8. Thermage, Inc. Announces First Quarter 2008 Results Release Date and Conference Call
9. Thermage, Inc. Announces Initial Shipments of Cellulite Product
10. Thermage Announces Fourth Quarter and Full Year 2007 Financial Results
11. Thermage, Inc. Announces Fourth Quarter 2007 Results Release Date and Conference Call
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/4/2009)...c. 4 While Congress deb...th care costs, Leapfrog,s purchaser members point ...ering the best quality care in the nation while at...our urban, eight children,s and three rural hospit...ased on results from The Leapfrog Hospital Survey....
(Date:12/4/2009)...tists at Johns Hopkins publishing in the December ...e by a gene called "Twist" may be the proverbial r... that drive aggressive, metastatic breast cancer f...ent work suggesting that it is a relatively rare s... breast cancer, scientists have surmised that this...
(Date:12/4/2009)...ntal tourism is a phenomenon that was started by p...high price of dental work in the US, Canada, and o...ental care, people have found that Mexican Dental ...tination. , (PRWEB) Decem...an 6 years, Mexican Dental Vacation is seeing thei...
(Date:12/4/2009)...RNewswire/ -- Substantial progress has been made o...s ability to diagnose and treat epilepsy and its c...ement has not reached most of the 50 million peopl...hree million people in the United States who have ...er, M.D., president of the American Epilepsy Socie...
(Date:12/4/2009)...ering drugs known as statins are among the most pr...researchers at Fred Hutchinson Cancer Research Cen...ransplant patients from one of the most serious co...ft-versus-host disease, or GVHD. The findings are ...l Blood . , In a retrospective study of 567 pati...
Breaking Medicine News(10 mins):Health News:The Leapfrog Group Releases Its 2009 Top Hospitals List 2Health News:The Leapfrog Group Releases Its 2009 Top Hospitals List 3Health News:Potential new 'twist' in breast cancer detection 2Health News:Potential new 'twist' in breast cancer detection 3Health News:Mexican Dental Vacation Sees a Rush Of New Patients: Recession A Factor 2Health News:Mexican Dental Vacation Sees a Rush Of New Patients: Recession A Factor 3Health News:Epilepsy Patients Caught in Treatment Gap and Not Getting State-of-the-Art Care 2Health News:Epilepsy Patients Caught in Treatment Gap and Not Getting State-of-the-Art Care 3Health News:Epilepsy Patients Caught in Treatment Gap and Not Getting State-of-the-Art Care 4Health News:Cholesterol-lowering drugs also may protect stem cell transplant patients from GVHD 2
...r osteoarthritis of the knee back to the future.Th...helps relieve pain and other symptoms better than ...ation of leeches to treat pain is an ancient medic...s, such as in treating postoperative complications...
...by viral cold are common in preschoolers. These at... frequency disappears by school age. //The current...eroids at the first sign of an attack. But whether...atory symptoms or the need for hospital admission....
...diagnosed with type 2 diabetes and now research sh...eater risk for a heart attack and stroke. //Specif...d with type 2 diabetes are 14-times more likely to...oing to get heart disease, heart attacks and strok...
...soon be fighting a losing battle. Scientists from ...uccessfully stopped the tuberculosis pathogen's ab...cally hides out in the immune system in a cell cal...s TB. Thus far, all of the research has been done ...
...on condition that can be fatal. It is defined as a...lly due to a blood clot, //which blocks a coronary...for a pulmonary embolism, a new study shows a new ...t 600,000 Americans develop a pulmonary embolism a...
...eir mouths. But as children get older, they become...y if they have not tried it before. Green veget... scientists say thousands of years ago toxins in p...ous of certain food types as youngsters. Resear...
Other Medicine News:
(Date:12/4/2009)...Neb., Dec. 4 Amber Pharmacy announ...creditation Commission for Health Care, Inc. (ACHC... years, Amber Pharmacy has provided comprehensive ...ique needs of specialized conditions. Amber Pharma...transplant programs. They work with over 170 trans...
(Date:12/4/2009)...AKE CITY, Dec. 4 Dynatro... signed a sole-source vendor agreement to provide ...Physical Therapy with 65 clinics located in Tennes...d the sole-source supplier to Benchmark Physical T...esident of sales and marketing at Dynatronics. "Be...
(Date:12/4/2009)..., WASHINGTON, Dec. 4 /PRNewswire-USNewswire/ ...eport published by the Pharmaceutical Research a...fies 97 new drugs and vaccines in development for ...ort found that the 97 products in development inc...e either in human clinical trials or awaiting appr...
Breaking Medicine Technology:Amber Pharmacy Earns Accreditation From ACHC 2U.S. Pharmaceutical Companies Developing 97 New Drugs and Vaccines to Fight HIV/AIDS 2FDA Approves Tekturna HCT 28R 29 as Initial Treatment in Patients Unlikely to Achieve Their Blood Pressure Goals With a Single Agent 4755 1FDA Approves Tekturna HCT 28R 29 as Initial Treatment in Patients Unlikely to Achieve Their Blood Pressure Goals With a Single Agent 4755 2FDA Approves Tekturna HCT 28R 29 as Initial Treatment in Patients Unlikely to Achieve Their Blood Pressure Goals With a Single Agent 4755 3FDA Approves Tekturna HCT 28R 29 as Initial Treatment in Patients Unlikely to Achieve Their Blood Pressure Goals With a Single Agent 4755 4FDA Approves Tekturna HCT 28R 29 as Initial Treatment in Patients Unlikely to Achieve Their Blood Pressure Goals With a Single Agent 4755 5FDA Approves Tekturna HCT 28R 29 as Initial Treatment in Patients Unlikely to Achieve Their Blood Pressure Goals With a Single Agent 4755 6FDA Approves Tekturna HCT 28R 29 as Initial Treatment in Patients Unlikely to Achieve Their Blood Pressure Goals With a Single Agent 4755 7U S Census Bureau Daily Feature for July 21 52174 1UPDATE 3A US Oncology Research Network Participates in Phase III Follow up Study to BiPars Investigational Cancer Drug BSI 201 4753 1UPDATE 3A US Oncology Research Network Participates in Phase III Follow up Study to BiPars Investigational Cancer Drug BSI 201 4753 2UPDATE 3A US Oncology Research Network Participates in Phase III Follow up Study to BiPars Investigational Cancer Drug BSI 201 4753 3UPDATE 3A US Oncology Research Network Participates in Phase III Follow up Study to BiPars Investigational Cancer Drug BSI 201 4753 4
...07 /CNW/ - Protox,Therapeutics Inc. (TSX-V:PRX) to...Phase 1 clinical trial evaluating ,PRX302 in patie...owing radiation failure. The trial results indica...ws promising signs,of therapeutic activity followi...The completion of the PRX302 Phase 1 trial is enco...
...P-233) Ability to Clear Brain,Plaque and Empower R...o ,Proof of Concept, Study Proposes Direct Correla...ry Recovery , LAS VEGAS, July 10, 2007 (PRIME NEWS..., a developer of innovative drugs,is pleased to a...ficacy in its ability to dramatically decrease bet...
Other Medicine Technology:Protox Announces Positive Clinical Data from Prostate Cancer Study 2Protox Announces Positive Clinical Data from Prostate Cancer Study 3Protox Announces Positive Clinical Data from Prostate Cancer Study 4Protox Announces Positive Clinical Data from Prostate Cancer Study 5Samaritan's Alzheimer's Drug Caprospinol Suggests Brain May be Able,to Heal From Alzheimer's Disease 2Samaritan's Alzheimer's Drug Caprospinol Suggests Brain May be Able,to Heal From Alzheimer's Disease 3
Surgiflex® WAVE XP™ Handpiece and Pump, without probe shaft
Surgiflex® WAVE XP™ Handpiece and Pump
SUCTION IRRIGATION: StrykeFlow PS
SUCTION IRRIGATION: StrykeFlow 2
Medicine Products: